Clinical Trial Search

Primary: Number of Participants by of Adverse Events Following a Skin Test Procedure — 1; 3; 0; 0 participants

Primary: Change From Baseline to Endpoint in Number of Contiguous Activated Voxels Meeting Predefined Threshold in Dorsolateral Prefrontal Cortex (DLPFC) on Functional Magnetic…

Primary: Percentage of Participants With an Occurrence of Biopsy Proven Acute Rejection (BPAR) During the First 3 Months Post de Novo Liver Transplantation. — 33.3; 32.9…

Primary: Early Phase Allergic Response After Treatment With Study Drug in Active and Placebo Patients — 9.3; 5.6; 23.1; 11.8 Percentage of EAR

Primary: Change in Number of Unique Bacterial Isolates From Pre-skin Preparation to Post-CABG - Sternal Site — -1.34; -1.31 isolates — p=0.655

Primary: Percent of Patients Who Achieved a EULAR (The European League Against Rheumatism) Response at Week 10 — 49.7 Percentage

Primary: Pain Score — 7.1; 6.4; 6.9 Units on a scale

Primary: Percentage of Participants With Less Than 2 Joint Bleeds During the 9-month Treatment Period — 72.7; 84.6; 75.0 Percentage of participants

Primary: Change in Mean Sitting Systolic Blood Pressure After 6 Weeks — 166.8; 168.5; 135.5; 142.5 mmHg

Primary: Number of Subject With Serious Treatment Emergent Adverse Events (TEAE) — 0; 0 Subjects

Primary: Change in Eczema Area Severity Index (EASI) Score From Baseline (Week 1) to Week 16. — 26.4 Scores on a scale.

Primary: Number of Participants Considered in Failure for the Primary Failure Endpoint at 3 Months — 36; 47; 16; 18 Participants

Primary: Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12 — -3.26 Number of Episodes

Primary: Change From Baseline in Trough Seated DBP at Week 8(LOCF). — -11.1; -7.3 mm Hg — p=<0.0001

Primary: Cholesteryl Ester Fractional Clearance Rate